Diffusion has completed enrollment in a Phase II clinical trial of patients with newly diagnosed primary brain cancer (GBM). In this open label trial, TSC is being dosed concomitantly with radiation therapy to evaluate TSC‘s effect on tumor control, quality of life and survival. The study is being conducted at 18 leading cancer centers throughout the United States.
Diffusion has been granted an FDA Orphan Designation for the use of TSC in this indication. For further information about the trial visit http://www.clinicaltrials.gov/ct2/show/NCT01465347?term=tsc&rank=4